Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis

被引：26

作者：

Kelley, TW

Alkan, S

Srkalovic, G

Hsi, ED

机构：

[1] Cleveland Clin Fdn, Dept Clin Pathol, Cleveland, OH 44195 USA

[2] Loyola Univ, Ctr Med, Dept Pathol, Maywood, IL USA

[3] Cleveland Clin Fdn, Dept Hematol & Med Oncol, Cleveland, OH 44195 USA

[4] Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA

来源：

LEUKEMIA RESEARCH | 2004年 / 28卷 / 08期

关键词：

bortezomib; chronic lymphocytic leukemia; proteasome inhibitor; NF-kappa B;

D O I：

10.1016/j.leukres.2003.12.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

New options are needed for the treatment of B-cell chronic lymphocytic leukemia (CLL). Proteasome inhibitors represent a potential therapeutic strategy. One such agent, bortezomib, was recently approved for the treatment of refractory multiple myeloma. In this study, lymphocytes were isolated from the blood of CLL patients, treated in vitro with bortezomib, and evaluated for apoptosis by flow cytometry. Bortezomib promoted apoptosis in CLL cells in a dose- and time-dependent manner. At 18 h incubation time, 10 nM bortezomib induced an average 4.27 fold (+/-2.57) increase in the percentage of apoptotic cells versus untreated controls. These data indicate that bortezomib has in vitro activity in CLL and support further investigations of this promising new drug. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：845 / 850

页数：6

共 50 条

[41] Synergistic effects of cisplatin and proteasome inhibitor bortezomib on human bladder cancer cells
Konac, Ece
Varol, Nuray
Kiliccioglu, Ilker
Bilen, Cenk Y.
ONCOLOGY LETTERS, 2015, 10 (01) : 560 - 564
[42] Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors
Pei, XY
Dai, Y
Grant, S
CLINICAL CANCER RESEARCH, 2004, 10 (11) : 3839 - 3852
[43] Novel paradigm to induce apoptosis in chronic lymphocytic leukemia cells
Patz, M.
Frenzel, L. P.
Pallasch, C. P.
Claasen, J.
Brinker, R.
Linde, N-F
Wendtner, C-M
ONKOLOGIE, 2010, 33 : 238 - 238
[44] THE PROTEASOME INHIBITOR BORTEZOMIB MODULATES THE EFFECT OF GLUCOCORTICOID TREATMENT IN PREDNISONE-RESISTANT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA CELLS
Junk, S.
Lauten, M.
Cario, G.
Wittner, N.
Schlegelberger, B.
Schrappe, M.
von Neuhoff, N.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 233 - 233
[45] Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells
de Frias, Merce
Iglesias-Serret, Daniel
Cosialls, Ana M.
Coll-Mulet, Llorenc
Santidrian, Antonio F.
Gonzalez-Girones, Diana M.
de la Banda, Esmeralda
Pons, Gabriel
Gill, Joan
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (12): : 1698 - 1707
[46] Bortezomib and paclitaxel synergistically induce apoptosis in chronic myelogenous leukemia cells
Bucur, Octavian
Stancu, Andreea L.
Petrescu, Stefana M.
Khosravi-Far, Roya
CANCER RESEARCH, 2010, 70
[47] The histone deacetylase inhibitor SAHA induces caspase-dependent apoptosis in chronic lymphocytic leukemia cells
Lagneaux, L
Meuleman, N
Delforge, A
Dejeneffe, M
Massy, M
Mortier, C
Bron, D
BLOOD, 2005, 106 (11) : 347A - 348A
[48] The histone deacetylase inhibitor SAHA induces caspase-dependent apoptosis in chronic lymphocytic leukemia cells
Lagneaux, L.
Meuleman, N.
Delforge, A.
Dejeneffe, M.
Massy, M.
Mortier, C.
Bron, D.
ACTA CLINICA BELGICA, 2006, 61 (02): : 101 - 101
[49] Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells
Grant Dewson
Roger T Snowden
Jason B Almond
Martin J S Dyer
Gerald M Cohen
Oncogene, 2003, 22 : 2643 - 2654
[50] Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells
Dewson, G
Snowden, RT
Almond, JB
Dyer, MJS
Cohen, GM
ONCOGENE, 2003, 22 (17) : 2643 - 2654

← 1 2 3 4 5 →